• ipharmaservices

Novartis presented robust clinical trial data of asciminib for chronic myeloid leukemia

Novartis has presented the clinical trial data of its STAMP inhibitor asciminib (ABL001) in patients with chronic myeloid leukemia.




The company has presented the Phase 3 ASCEMBL trial results in which asciminib has shown statistically significant superiority in major molecular response (MMR) versus bosutinib. ASCEMBL is a Phase 3, multicenter, open-label randomized study, comparing the efficacy of asciminib versus bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia.


Also read: BMS announced to acquire Forbius, targets to strengthen oncology and fibrosis portfolio


The drug is indicated in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase previously treated with two or more tyrosine kinase inhibitors (TKIs). Patients who failed after treatment with the recently administered TKI inhibitor were included in the trial.

Also read: FDA issued Emergency Use Authorization of Convalescent Plasma for COVID-19 treatment


Despite the availability of multiple treatment options for chronic myeloid leukemia, increased resistance and tolerance have been reported with sequential TKI inhibitors. Asciminib inhibits the ABL myristoyl pocket, thereby addressing the issue of resistance and intolerance.


Asciminib has received Fast Track designation from the US FDA.


Also read: Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma

For pipeline, market overview, SLRs, and market access reports (syndicate and customised) please write to sales@firstviewinsight.com


For all syndicate reports: Click here

Recent Posts

See All

Please donate to support iPharmaCenter. Click on donate button in header to support us. Thank you

©2020 by ipharmaservices